Zeroing in on neurodegenerative α -synuclein

Nature Reviews Drug Discovery 16, 371 (2017). doi:10.1038/nrd.2017.95 Author: Katie Kingwell In the search for the first disease-modifying therapy for Parkinson disease, drug developers are advancing α-synuclein-targeted agents into proof-of-concept clinical trials.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research